Educational Grant Research Articles

KILT: A RANDOMIZED NON‐COMPARATIVE PHASE II LYSA STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA

Background: Peripheral T-cell Lymphoma (PTCL) is a heterogeneous group of mature T-cell lymphomas (TCL) with adverse outcomes. Current treatment options for relapsing PTCL are limited. KIR3DL2 is a killer immunoglobulin-like receptor that is expressed across different subtypes of TCL, including approximately 40% of PTCL. Lacutamab is a humanized first-in-class monoclonal antibody designed to deplete KIR3DL2-expressing cells via ADCC and phagocytosis. In a previous phase I trial in relapsed/refractory cutaneous TCL, lacutamab showed adequate safety profile with no dose limiting toxicities and a global response rate of 43%. TELLOMAK multi-cohort phase II trial (NCT03902184) in advanced TCL is ongoing. Lacutamab has not been previously investigated as a combination therapy. Preclinical studies have shown that lacutamab selectively killed KIR3DL2-positive primary cells ex vivo from patients with PTCL. A combination of lacutamab with gemcitabine and oxaliplatin (GemOx) enhances NK cell anti-tumor activity in vitro. Methods: This is an open label, multi-center, international, randomized non-comparative phase II trial to compare the safety and efficacy of lacutamab in combination with GemOx vs. GemOx alone in patients with any subtypes of relapsed/refractory KIR3DL2-positive PTCL. The design is non comparative meaning that the control arm will ensure that the assumptions used for sample size calculation are verified. For that reason, randomization is unbalanced in favor of the experimental arm (2:1). Patients are stratified according to R/R status and should have received ≤2 prior systemic therapies. In the experimental arm, patients are treated for 6 cycles of lacutamab 750 mg (intravenous infusion) + GemOx every 3 weeks as induction, and with lacutamab every 4 weeks as maintenance for up to a maximum of 2 years if they reached at least a partial response after induction. All patients should have a KIR3DL2 expression ≥1% as assessed centrally by immunohistochemistry. The primary endpoint is the median modified progression-free survival using the Lugano 2014 criteria. Secondary endpoints include safety, other efficacy endpoints and exploratory biomarker analyses. 56 patients are planned to be enrolled in France, Belgium, Spain and Germany. The trial is currently enrolling in 37 medical centers in France and Belgium. The sponsor of the trial is the Lymphoma Academic Research Organisation (LYSARC) in collaboration with Innate Pharma. Trial registration: NCT04984837. The research was funded by: The research was funded by Innate Pharma Keywords: aggressive T-cell non-Hodgkin lymphoma, immunotherapy, ongoing trials Conflicts of interests pertinent to the abstract. M. Cheminant Research funding: Innate Pharma J. Bruneau Research funding: Innate Pharma C. Herbaux Honoraria: AbbVie, Janssen, Roche, Gilead Research funding: AbbVie A. Wolfromm Consultant or advisory role Takeda O. Tournilhac Honoraria: Amgen, Janssen, Gilead, Abbvie, BluePrint, Roche Educational grants: Amgen, Janssen, Gilead, Abbvie, BluePrint, Roche P. Gaulard Research funding: Innate Pharma N. Ortonne Research funding: Innate Pharma O. Hermine Research funding: Innate Pharma

TESTICULAR LARGE B‐CELL LYMPHOMA IS GENETICALLY SIMILAR TO PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA AND DISTINCT FROM NODAL DIFFUSE LARGE B‐CELL LYMPHOMA

Introduction: Testicular large B-cell lymphoma (TLBCL) is an infrequent and aggressive lymphoma presenting in an immune-privileged site, recently recognized as a distinct entity from diffuse large B-cell lymphoma (DLBCL). Here, we performed the genetic characterization of TLBCL and compare it with a published series of nodal DLBCL and primary central nervous system lymphoma (PCNSL). Patients and Methods: We collected 61 patients with TLBCL diagnosed between 2002 and 2021. Cell-of-origin was determined by immunochemistry and Lymph2Cx assay. To characterize the genomic profile of TLBCL we performed targeted next-generation sequencing, copy number arrays, and fluorescent in situ hybridization, and compared them to those of DLBCL and PCNSL. Results: The median age was 70 years and 30% of the patients had disseminated disease at diagnosis, including six cases with CNS involvement. Using Hans' algorithm, 83% (44/53) were identified as a non-germinal center while the Lymph2Cx assay categorized 71% (30/42) as activated B-cell phenotype and 12% (5/42) as unclassified. BCL6 rearrangements were detected in 36% (17/47) of cases, and no concomitant BCL2 and MYC rearrangements were found. Integrative analysis of 40 cases with single nucleotide variants, indels, and copy number alterations (CNA) data showed that the most frequent alterations (>50%) in TLBCL were PRDM1, CDKN2A/B, TNFAIP3, SGK1, ARID1B, MYD88L265P, SPIB, PIM1, and CD79B (Figure). Concomitant variants in MYD88L265P, CD79B, and PIM1 were detected in twelve (29%) cases. Using the LymphGen tool, 71% (30/42) of the cases could be classified into a molecular subgroup, with MCD being the most frequent group (66%, 20/30). Interestingly, patients with localized or disseminated disease displayed similar genomic complexity based on the number of CNAs and the number of mutated genes. Compared with nodal DLBCL, localized and disseminated TLBCL have less CNA complexity (P = 0.01 and P < 0.04, respectively) but showed a higher number of variants (P = 0.01 and P < 0.001, respectively). TLBCL also presented more frequently 18q21.32-q23 (BCL2) gains and 6q and 9p21.3 (CDKN2A/B) deletions. PIM1, MYD88L265P, CD79B, TBL1XR1, MEF2B, CIITA, EP300, and ETV6 variants were enriched in TLBCL, and BCL10 mutations in nodal DLBCL. There were no genetic differences between TLBCL and PCNSL. Encore Abstract - previously submitted to regional or national meetings (up to <1’000 attendees). The research was funded by: Asociación Española Contra el Cancer AECC/CIBER: PROYE18020BEA (SB); Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III Instituto de Salud Carlos III, “Cofinanciado por la Unión Europea” and Fondos FEDER: European Regional Development Fund “Una manera de hacer Europa”: PI17/01061 (SB), PI19/00887 (ALG and EG), and INT20/00050 (ALG); Marató TV3 TV3-Cancer/ 201904-30 (SB). ARD is supported by a grant from Sociedad Española de Hematología y Hemoterapia. CL is supported by postdoctoral Beatriu de Pinós grant from Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya and by Marie Sklodowska-Curie COFUND program from H2020 (2018-BP-00055). Keywords: Extranodal non-Hodgkin lymphoma, Pathology and Classification of Lymphomas Conflicts of interests pertinent to the abstract. F. Nadeu Honoraria: Janssen, AbbVie E. Campo Consultant or advisory role: Takeda, NanoString, AbbVie, Illumina Honoraria: Janssen, EUSPharma, Roche Research funding: AstraZeneca A. López-Guillermo Consultant or advisory role: Roche, Gilead, Kite Pharma, Celgene, Bristol Myers Squibb, Incyte, Takeda, Kern Pharma, Pfizer, Janssen Honoraria: Janssen, Roche, Kite Research funding: Gilead, Janssen, Celgene, Bristol Myers Squibb Educational grants: Roche, Kite/Gilead

MYC ALTERATIONS IN HIV‐ASSOCIATED B CELL LYMPHOMAS: RESULTS OF “EUROMYC” STUDY (A EUROPEAN RETROSPECTIVE STUDY)

Introduction: HIV negative patients (pts) with B cell lymphoma (Ly) carrying MYC rearrangements and BCL2+/-BCL6 translocations [double hit (DHL) or triple hit Ly (THL)] have shown a dismal prognosis when treated with standard chemotherapy. Data about the prognosis of “single hit” Ly, (SHL) are more controverse. In HIV-associated B cell lymphomas (HIV+Ly), scanty data are available on the prevalence and prognostic impact of MYC rearrangements. Methods: This is a retrospective study conducted in 11 European centers with the aim to evaluate the clinical and prognostic impact of MYC rearrangement, evaluated by FISH analysis, in HIV+Ly. We compared HIV+ Ly [diffuse large B cell Ly (DLBCL), B cell Ly unclassifiable, with features intermediate between DLBCL and Burkitt (BCLU), and High grade B cell Ly (HGBL)] with (MYC+) and without (MYC-) MYC rearrangements, treated with standard (R-CHOP or CHOP like) or intensive therapy (iCT) that is, CODOX-IVAC, Carmen trial, GMALL. Results: A total of 161 consecutive pts were enrolled: 49 (30%) were MYC+ and 112 (70%) MYC-. MYC+ pts had higher involvement of central nervous system (CNS) at presentation, higher ki67%, more frequent histology other than DLBCL, translocation of BCL2 and germinal center B phenotype. MYC+ pts received more frequently iCT (45% vs. 20%, p = 0.002). With a median follow-up of 57 months, there were no significant differences in overall survival (OS) and progression-free survival (PFS) between MYC+ and MYC- pts (5 years (y) OS and PFS 55% and 47% in MYC+ and 59% and 53% in MYC- pts). DHL/THL were 10 (13 MYC+ pts did not have data on BCL2/BCL6): compared to 26 SHL they had similar clinical characteristics, but worse outcome with 5y PFS (30% vs. 60%, p = 0.02) and 5y OS (50% vs. 67%, p = 0.07). In univariate analysis IPI≥3, ECOG≥ 2, increased LDH and ki67 < 90% were related to worse OS and PFS while BCL2 translocation with shorter PFS. In multivariate analysis ECOG≥2, elevated LDH and ki67 < 90% maintained their negative impact. In MYC+ pts, iCT was related to better PFS compared to standard therapy (5 y PFS 62% and 35%, p = 0.04) and to a trend of better OS (5 y OS 61% and 52%, p = 0.25) (Figure 1). No pts treated with iCT died from toxicity. Keyword: aggressive B-cell non-Hodgkin lymphoma Conflicts of interests pertinent to the abstract M. Spina Honoraria: GILEAD, Servier, Novartis, Incyte, BeiGene, Istituto Gentili Research funding: MENARINI L. Arcaini Consultant or advisory role Roche, Janssen-Cilag, Verastem, Incyte, EUSA Pharma, Celgene/Bristol Myers Squibb, Kite/Gilead, ADC Therapeutics Research funding: Gilead Sciences Other remuneration: Speakers’ Bureau: EUSA Pharma, Novartis D. Dalu Educational grants: Roche, Gentili, Lilly and Eisai Other remuneration: Gentili, Daikii Sanchio A. Tucci Consultant or advisory role Gentili, Sanofi, Jannsen Honoraria: Kiowa Kyrin, Takeda

REMISSION AFTER CAR T‐CELLS: DO PATIENTS RECOVER A NORMAL LIFE?

Introduction: CD19 CAR T-cells can induce prolonged remission in a significant number of patients with relapse/refractory (R/R) lymphoma. However, little is known about patients’ life after CAR T-cell therapy. Here, we conducted a prospective study to evaluate health-related quality of life (HRQol), as well as physical, social and professional outcomes after CAR T-cell therapy. Methods: This prospective study was conducted at the University Hospitals of Rennes and Toulouse (France). All adult patients with R/R lymphoma treated with CAR T-cells were eligible. HRQol changes were assessed using the FACT-Lym questionnaire. Other questionnaires evaluated cognitive state (FACT-Cog), fatigue (FACT-Fatigue), anxiety and depression (HAD scale), post-traumatic stress disorder (PTSD), and sexuality (Vican). Questionnaires were collected at baseline (before leukapheresis), immediately before CAR-T infusion, 3 and 6 months after CAR T-cell infusion. Patients were censored in case of relapse or death. Among patients in remission after 12 months, professional, physical, sexual and global life information were collected. Results: From March 2020 to August 2022, 59 patients were included in the study (46 LBCL, 5 MCL, 8 FL). Median age was 63 years (range, 19–78). Patients were treated with axi-cel (N = 37), tisa-cel (N = 18) or brexu-cel (N = 3). The median follow-up after CAR T-cell infusion was 11 months. There were 53 and 38 still in remission at 3 and 6 months after CAR T-cell infusion, respectively. The FACT-Lym score showed a clinically relevant improvement of HRQol, with a mean change from baseline of 10.9 points (95%CI 5.8; 16.1) and 12.2 (95%CI 4.2; 20.1), respectively. The fatigue subscale showed a clinically relevant improvement at 3 and 6 months, with a mean change from baseline of 5.9 points (95%CI 2.9; 8.8) and 4.7 (95%CI 0.2; 9.2), respectively. The FACT-Cog score did not show any clinically relevant change. The HAD score showed that 43% and 24% of patients presented anxiety and depression at baseline, respectively, versus 26% and 7% after 6 months. Overall, 26% of patients presented a significant PTSD (i.e., >44) at 6 months. 54.5% of the patients considered that their life was back to normal (before lymphoma diagnosis); 68.2% patients were satisfied with their sexual life, 59.1% considered that it was back to normal; 54% felt less fit than before lymphoma; 21/21 patients practicing a physical activity before lymphoma resumed their activity; 3/8 resumed their social activity; Among the working age population (n = 10), 50% patients had returned to work. Encore Abstract - previously submitted to EHA 2023 Keywords: Aggressive B-cell non-Hodgkin lymphoma, Cellular therapies, Other Conflicts of interests pertinent to the abstract F. Colin Consultant or advisory role Gilead, Novartis A. Anota Consultant or advisory role AMGEN, IPSEN, ASTRAZENECA, KITE-GILEAD Educational grants: KITE GILEAD L. Ysebaert Consultant or advisory role AstraZeneca, Beigene, BMS/Celgene, Janssen, Gilead/Kite R. Houot Consultant or advisory role Kite/Gilead Honoraria: Bristol Myers Squibb/Celgene, MSD, Kite/Gilead, Roche, Novartis, Janssen A. Moignet Consultant or advisory role Kite, Novartis

Olaparib in HR-deficient (HRD), metastatic triple-negative breast cancer (TNBC) and relapsed ovarian cancer (ROC) without germline mutations in BRCA1 or BRCA2: Phase 2 EMBRACE trial.

e15079 Background: Homologous recombination deficiency (HRD) caused by germline BRCA1/2 mutations (gBRCAm) sensitize high grade serous ovarian cancers (HGSOC) and TNBC to PARP inhibitors (PARPi) such as olaparib. Loss of function of BRCA1 or RAD51C, due to promoter methylation or mutation of non-BRCA HR genes may also confer sensitivity to PARPi. This investigator-initiated, proof-of-concept trial evaluated olaparib in platinum(Pt)-sensitive, relapsed HGSOC and metastatic TNBC, with HRD due to mechanisms other than gBRCAm. EMBRACE is the first trial evaluating PARPi in loss of function of BRCA1/ RAD51C by promoter methylation. Methods: Single-arm, phase 2 trial of olaparib 300 mg orally twice daily in adults with metastatic TNBC or Pt-sensitive relapsed HGSOC and HRD due to mechanisms other than gBRCAm. 1 line of prior Pt-chemotherapy was allowed (HGSOC); additional lines of non-Pt therapy were allowed (TNBC). Tumor BRCA1/RAD51C promoter methylation was determined by methylation-sensitive high-resolution melting PCR and next generation sequencing (NGS, Pillar Biosciences BRCA1 &amp; RAD51C Methylation test, high methylation threshold 70%). Unmethylated cases underwent NGS HR gene mutation testing (Pillar Biosciences HRD test, paired tumor/normal). The primary outcome was objective tumor response rate (OTRR) at 6 months(m). Secondary objectives: progression-free survival (PFS), OTRR according to HR gene mutation type, safety. Tertiary: associations between biomarkers and clinical outcomes. Results: 22 participants (15 HGSOC, 7 TNBC) enrolled from 208 screened (Sep 2018 - Mar 2022). Methylation was detected in 8/15 HGSOC (all BRCA1) and 5/7 TNBC (4 BRCA1, 1 RAD51C). Both cohorts included mutations in gBRIP1 (1), gPALB2 (1), gRAD51C (3), sBRCA1 (2), with 1 COSMIC mutational signature 3, and 1 positive HRD score in HGSOC. OTRR at 6m was 40% in HGSOC (6/15: 5 partial, 1 complete), and 0% in TNBC (0/7). OTRR was 38% (3/8) in methylated tumors vs 43% (4/7) with other HRD. Stable disease at 6m was 47% (7) in HGSOC and 43% (3) in TNBC durations were 7m in HGSOC and 3m in TNBC. PFS was 53% at 6m and 25% at 12m in HGSOC, vs 17% at 6m and NE at 12m in TNBC. TNBC 2-3 prior lines of therapy. Conclusions: Olaparib demonstrated clinically relevant activity in HGSOC without gBRCAm. Objective responses were seen in HGSOC with methylated BRCA1. Olaparib had limited activity in heavily pre-treated TNBC. Further research is needed into the effects of non-Pt chemotherapy on methylation of BRCA1/RAD51C to improve selection of HGSOC and TNBC for PARPi. (ANZCTRN12617000855325) Acknowledgements: Funding from Cancer Australia and the NBCF(PS-15-048), provision of study drug plus an untied educational grant from AstraZeneca and its group of companies. EMBRACE was led by the NHMRC CTC, University of Sydney in collaboration with ANZGOG, BCT-ANZ, and GCCTI. Clinical trial information: ACTRN12617000855325 .

Advancing Member Expertise with the Support of Educational Grants

Article| June 2023 Advancing Member Expertise with the Support of Educational Grants Susan Carlson, MSEd Susan Carlson, MSEd Search for other works by this author on: This Site PubMed Google Scholar ASA Monitor June 2023, Vol. 87, 7. https://doi.org/10.1097/01.ASM.0000938780.50295.75 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Cite Icon Cite Get Permissions Search Site Citation Susan Carlson; Advancing Member Expertise with the Support of Educational Grants. ASA Monitor 2023; 87:7 doi: https://doi.org/10.1097/01.ASM.0000938780.50295.75 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll PublicationsASA Monitor Search Advanced Search Topics: knowledge acquisition Health care continues to evolve, and the anesthesiology community must evolve in tandem. Ensuring our members have access to cutting-edge education to advance their knowledge and earn CME is a must. To help achieve this goal, grants provided by corporate partners enable us to offer more educational programming, address new knowledge gaps, and deliver courses at low, or no, cost to members. “ASA uses grants to develop courses that meet learning gaps and give our members more opportunities to fill MOCA® requirements,” explained Edward Mariano, MD, MAS, FASA, Chair of ASA's Section on Education and Research. “We are committed to offering optimal learning experiences. That means ensuring members are engaged at the highest level, have a goal for learning, and have opportunities to put what they learned into action and reflect on the impact of their educational experiences on clinical practice.” Courses funded by corporate grants aren't just being... You do not currently have access to this content.

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.

Introduction: The primary analysis of the Ro-CHOP trial (NCT01796002) demonstrated that romidepsine (Ro) plus CHOP did not provide an increased efficacy compared with CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL). We report here the final analysis of the Ro-CHOP trial. Methods: The study was an open-label multicenter randomized (1:1) phase III study of Ro-CHOP versus CHOP as frontline treatment of patients 18–80 years with PTCL. The primary endpoint was progression-free survival (PFS) according to IWG 1999 criteria. Overall survival (OS) was a secondary endpoint, relapse patterns and PFS/OS after the first progression (PFS2/OS2) were analyzed post-hoc. The cut-off date was set to 2022/12/13, that is, five years after the last patient was enrolled. Results: 211 and 210 patients were assigned to receive 6 cycles of Ro-CHOP or CHOP in 3-week cycles, respectively. Median age was 65 (25–81) years. With a median follow-up of 71.8 months, 271 patients (64.4%) presented a PFS event by independent RAC assessment. Median PFS was 12 months (95% CI = [9; 25.8]) and 10.2 months ([7.4; 13.2]) for Ro-CHOP and CHOP, respectively (HR = 0.79 [0.62; 1.005], p = 0.054, 2-sided p-value). Based on 229 deaths, median OS was 62.2 months and 43.8 months for Ro-CHOP and CHOP, respectively. The causes of death were the following: lymphoma (n = 165, 72.4%), concurrent illness (n = 30, 13.2%), other reasons (n = 12, 5.3%), toxicity of salvage treatment (n = 8, 3.5%), toxicity of study treatment (n = 4, 1.8%), unknown (n = 9, 3.9%). No new safety signal was observed. A significantly prolonged PFS in the follicular helper T-cell (TFH) lymphoma subgroup (centrally reviewed) was still observed with this longer follow-up. The median PFS was 19.5 months ([11.5; 44.4]) in the Ro-CHOP arm and 10.6 months ([7.4; 14.9) the CHOP arm with a HR of 0.703 ([0.502; 0.985], p = 0.0395). Additional treatment was given to 251 patients after progression (Ro-CHOP = 115, and CHOP = 136), leading to an overall response rate of 35.7% (CR/CRu: 21.7%) and 31.6% (CR/CRu: 22.1%) in the Ro-CHOP and CHOP groups, respectively. Overall, 191 of the 251 patients (76.1%) progressed after second-line therapy, and 20 patients died without a second progression (8.0%). The median PFS2 and OS2 were 3.3 months (95% CI, [2.7; 4.5]) and 11.5 months ([9.6; 15.9]), respectively. Twenty-three patients (9.2%) received an allogeneic stem cell transplantation (median age 51 [29–70] years) and displayed 1-year PFS2 and OS2 rates estimated at 59.7% and 81.8%, respectively. Detailed outcome according to salvage treatment at progression will be presented at the meeting. The study was sponsored by the LYSARC, with funding provided by Celgene/BMS Keyword: aggressive T-cell non-Hodgkin lymphoma Conflicts of interests pertinent to the abstract V. Camus Consultant or advisory role: Roche, BMS, Novartis, Kite-Gilead, Janssen, Abbvie, Sanofi, Octapharma, Kyowa Kirin Pharma Research funding: Iqone Healthcare, BMS Educational grants: Pfizer, Roche, BMS, Novartis, Kite-Gilead M. Delfau-Larue Honoraria: Takeda, Amgen, Roche, Gilead, Abbvie Research Funding: Celgene, BMS, Roche

Lymph node location and retention properties of DC‐SIGN engagement with the Immunoglobulin Oligomannoses of Follicular Lymphoma

Introduction: The oligomannose-type glycans occupying the surface immunoglobulin antigen-binding site (sIg-Mann) are a tumor-founding post-translational requirement of classic follicular lymphoma (FL). These are universally acquired and a clonal necessity during the entire natural history of FL from the early stages throughout transformation into EZB-DLBCL (Chiodin G, Blood 2021, Odabashian M, Blood 2020). The low-affinity interaction of sIg-Mann with its specific ligand DC-SIGN distinguishes from conventional high-affinity antigen:Ig protein interactions for promoting prolonged low-level growth and prosurvival signals via PI3K/AKT and not endocytosis (Linley A, Blood 2015). However, the location and function of DC-SIGN remains to be further elucidated. Here, we investigated the hypothesis that the specific DC-SIGN:Ig-Mann interaction functions to promote retention of FL cells in tissue niches maintaining selective survival advantage. Methods: Immunofluorescence imaging was used to determine DC-SIGN histological location in primary FL lymph nodes. In WSU-FSCCL cells, DC-SIGN effects on sIg redistribution were measured by dSTORM; adhesion to VCAM-1 in presence/absence of inhibitors was measured by flow cytometry. Results: Immunofluorescence of lymph nodes from FL patients revealed that DC-SIGN was expressed on interfollicular CD163+ macrophages and, remarkably, on CD23+ follicular dendritic cells (FDC), claiming an influence on FL cell retention and survival. dSTORM revealed that DC-SIGN induced less dense and more diffuse surface Ig clusters compared to anti-Ig, reflecting an immature sIg redistribution unable to promote endocytosis and death. However, DC-SIGN efficiently induced adhesion of sIg-Mann+ve lymphoma cells to VCAM-1, known to be expressed on both lymph node macrophages and FDC, and inhibited migration towards SDF-1 in vitro. Blocking of DC-SIGN carbohydrate-recognition domain completely abrogated DC-SIGN-induced adhesion. Although intracellular signals were significantly lower, DC-SIGN induced levels of adhesion similar to those induced by anti-Ig. Adhesion to VCAM-1 was observed at concentrations from 20 µg/ml down to 20 ng/ml, even when AKT and ERK phosphorylation was not detectable. Either proximal inhibition of the PI3K/AKT pathway, or distal inhibition of ARP2/3, formin, and Cdc42 for lamellipodium formation at the surface membrane, suppressed adhesion. Conclusions: These results reveal an important mechanism of the DC-SIGN:sIg-Mann interaction that fine-tunes signals for membrane adaptation towards tumor cell adhesion, without promotion of cell death. This possibly facilitates FL cell retention in the lymph node protected tumor niche where selective growth and survival signals are maintained. Interrupting this interaction will be a novel way towards tumour-specific targeted therapy in FL patients. The research was funded by: This research was funded by Blood Cancer UK (grant 18009), Cancer Research UK (ECRIN-M3 accelerator award C42023/A29370, program C2750/A23669, and BTERP project C36811/A29101). D.T. was funded by the Eyles Cancer Immunology PhD scholarship, G.C. was funded by the Eyles Cancer Immunology Fellowship and the Southampton Cancer Immunology Centre Pump-priming award 2021). Keywords: Indolent non-Hodgkin lymphoma, Microenvironment, Targeting the Tumor Microenvironment Conflicts of interests pertinent to the abstract. F. Forconi Employment or leadership position: University of Siena Consultant or advisory role: Beigene Honoraria: Abbvie, Janssen-cilag, Beigene, Astra-Zeneca Research funding: Cancer Research UK Educational grants: Beigene, Abbvie Other remuneration: BC Platform

Is There a Role for Adjuvant Therapy in Patients with Large Juvenile Nasopharyngeal Angiofibromas?

The LaryngoscopeEarly View Triological Society Best Practice Is There a Role for Adjuvant Therapy in Patients with Large Juvenile Nasopharyngeal Angiofibromas? Charles A. Riley MD, Corresponding Author Charles A. Riley MD [email protected] orcid.org/0000-0002-1993-7018 Department of Otolaryngology—Head and Neck Surgery, Walter Reed National Military Medical Center, Bethesda, Maryland, USA Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA Send correspondence to Charles A. Riley, MD, Department of Otolaryngology—Head and Neck Surgery, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD 20889, USA. Email: [email protected]Search for more papers by this authorDavid A. Gudis MD, David A. Gudis MD orcid.org/0000-0002-1938-9349 Department of Otolaryngology – Head and Neck Surgery, Columbia University Medical Center, New York Presbyterian Hospital, New York City, New York, USASearch for more papers by this author Charles A. Riley MD, Corresponding Author Charles A. Riley MD [email protected] orcid.org/0000-0002-1993-7018 Department of Otolaryngology—Head and Neck Surgery, Walter Reed National Military Medical Center, Bethesda, Maryland, USA Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA Send correspondence to Charles A. Riley, MD, Department of Otolaryngology—Head and Neck Surgery, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD 20889, USA. Email: [email protected]Search for more papers by this authorDavid A. Gudis MD, David A. Gudis MD orcid.org/0000-0002-1938-9349 Department of Otolaryngology – Head and Neck Surgery, Columbia University Medical Center, New York Presbyterian Hospital, New York City, New York, USASearch for more papers by this author First published: 30 May 2023 https://doi.org/10.1002/lary.30797 Editor's Note: This Manuscript was accepted for publication on May 18, 2023 The authors have no other funding, or financial relationships to disclose. The authors whose names are listed above certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. The contents of this publication are the sole responsibility of the author(s) and do not necessarily reflect the views, opinions, or policies of Uniformed Services University of the Health Sciences (USUHS), the Department of Defense (DoD), the Departments of the Army, Navy, or Air Force. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. BIBLIOGRAPHY 1McAfee WJ, Morris CG, Amdur RJ, Werning JW, Mendenhall WM. Definitive radiotherapy for juvenile nasopahryngeal angiofibroma. Am J Clin Oncol. 2006; 29(2): 168- 170. 2Mallick S, Benson R, Bhasker S, Mohanti BK. Long-term treatment outcomes of juvenile nasopharyngeal angiofibroma treated with radiotherapy. Acta Otorhinolaryngol Ital. 2015; 35(2): 75- 79. 3Amdur RJ, Yeung AR, Fitzgerald BM, Mancuso AA, Werning JW, Mendenhal WM. Radiotherapy for juvenile nasopharyngeal angiofibroma. Pract Radiot Oncol. 2011; 1(4): 271- 278. 4Thakar A, Gupta G, Bhalla AS, et al. Adjuvant therapy with flutamide for presurgical volume reduction in JNA. Head Neck. 2011; 33(12): 1747- 1753. 5Labra A, Chavolla-Magana R, Lopez-Ugalde A, Alanis-Calderon J, Huerta-Delgado A. Flutamide as a preoperative treatment in juvenile angiofibroma (JA) with intracranial invasion: report of 7 cases. Otolaryngol Head Neck Surg. 2004; 130(4): 466- 469. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation

Effect of cardiac telerehabilitation as standard care on quality of life

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – EU funding. Main funding source(s): EIT Health education grant. Background Cardiac telerehabilitation (CTR) is a continuously developing cardiac rehabilitation (CR) format that might offer a solution to some of the challenges centre-based CR programs face. CR centres continue to face suboptimal participation in their provided CR program. The COVID-19 pandemic encouraged CR centres to implement their own CTR program to tackle practical challenges and to improve participation in CR. Multiple centres have since then developed a CTR program in accordance to (inter)national guidelines. CTR aims to improve the quality of life of patients, therefore analyses of quality of life is essential. Purpose Our study aims to analyse quality of life changes over a period of three months after program initiation for patients choosing to participate in either centre-based CR or CTR. Methods Our study included (N)STEMI patients eligible for CR between November 2021 and November 2022. Patients were invited by the cardiac rehabilitation nurse during intake to participate in CR. Patients were offered the choice between centre-based CR and CTR. The centre-based CR exercise program typically lasted for 6-8 weeks and the CTR program for a total of 48 weeks. CTR offers remote-access, digital platform for patients to interact with their healthcare professionals. The digital platform monitors physical activity and progress, which can be access by both patients and coaches. Coaches provide remote-access feedback. The SF-36 questionnaire was send out right after the CR intake procedure (T0) and three months after the CR intake procedure (T1). We only analysed data from participants who completed both T0 and T1 questionnaires, using the paired sample T-test for both CTR and centre-based CR. Results Until now, 173 patients have been included in the study of which 42 patients (24%) participated in CTR. 143 patients reached T1. 84 (59%) participants completed both T0 and T1 questionnaires, of which 24 (29%) participate in CTR (92% male, mean age 60) and 60 (71%) participate in centre-based CR (80% male, mean age 64). Participants from the centre-based CR program improved on both physical (score: +11,12; p &amp;lt; 0,001) and emotional (score: +9,30; p = 0,028) role functioning over a three month period. Participants in the CTR program improved on physical role functioning (score: +18,75; p = 0,002) and social functioning (score: + 13,54; p = 0,019). Conclusion Our preliminary show that patients were able to improve quality of life in both CTR and centre-based CR. Therefore, CTR can be used as an alternative to centre-based CR as standard care. Future research should focus on long term effects on quality of life.

The operational approach to and challenges of high-technology clinical simulation in South Africa

Background. Research has been published on the application of high-technology clinical simulation as a training tool in South Africa (SA). However, littlehas been published on the operational approach taken and challenges faced when establishing and running a high-technology clinical simulation facility.Objective. To ascertain the current operational approach taken and challenges faced regarding high-technology clinical simulation by SA simulation facilities.Methods. A quantitative descriptive study with an online questionnaire survey was conducted with representatives of simulation facilities at SA publichealth professions training institutions where high-technology simulation is used. The questionnaire consisted of sections dealing with the characteristics ofand challenges faced by the facilities and the following operational aspects: management, funding, staffing and staff development, curriculum integration,physical environment and research.Results. Forty-two institutions were approached and 23 (54.8%) participated. Simulation was used at 16 (69.6%) of these institutions, representing17 facilities, with 14 (82.4%) using high-technology simulation. Nine (64.3%) of the 14 simulation facilities were custom built. Four (28.6%) facilitieshad dedicated technical staff. The participating simulation facilities acquired their funding mainly through institutional budget allocations (78.6%) andgovernment education grants (78.6%). The number of students using high-technology simulation facilities was the highest among the fifth-year (median195) and sixth-year (median 21) students.Conclusion. Large student groups and a lack of trained simulation staff are some of the challenges being faced by high-technology simulation facilities in SA.Recommendations and guidelines should be established to ensure effective integration and alleviation of all operational aspects and challenges

Industry Payments to Radiologists During the Last 5 Years and Impact of COVID-19 Pandemic

ObjectiveThe aim of this study is to assess the trends in industry payments to radiologists and the impact of the COVID-19 pandemic, including trends in different categories of payments. MethodsThe Open Payments Database from CMS was accessed and analyzed for the period from January 1, 2016, to December 31, 2021. Payments were grouped into six categories: consulting fees, education, gifts, research, speaker fees, and royalties or ownership. The total number, value, and types of industry payments to radiologists were subsequently determined and compared pre- and postpandemic from 2016 to 2021. ResultsThe total number of industry payments and the number of radiologists receiving these payments dropped by 50% and 32%, respectively, between 2019 and 2020, with only partial recovery in 2021. However, the mean payment value and total payment value increased by 177% and 37%, respectively, between 2019 and 2020. Gifts and speaker fees experienced the largest decreases between 2019 and 2020 (54% and 63%, respectively). Research and education grants were also disrupted, with the number of payments decreasing by 37% and 36% and payment value decreasing by 37% and 25%, respectively. However, royalty or ownership increased during the first year of the pandemic (8% for number of payments and 345% for value of payments). ConclusionsThere was significant decline in overall industry payments coinciding with the COVID-19 pandemic, with biggest declines in gifts and speaker fees. The impact on the different categories of payments and recovery in the last 2 years has been heterogeneous.

Interferon gamma supresses T follicular helper cell and antibody responses upon viral infection

Abstract Although humoral and cellular immunity upon viral infections usually co-exist, sometimes one of the two responses emerges as dominant and is responsible for most of the antiviral activity. For example, vesicular stomatitis virus (VSV) infection induces early and potent neutralizing antibody (nAb) responses, whereas lymphocytic choriomeningitis virus (LCMV) infection induces strong cellular responses, but weak nAb responses. Recent work from our laboratory has shown that unbalance is observed also at the level of CD4 T cells responses, with subcutaneous VSV infection inducing strong T FHpolarization that supports nAb responses, and subcutaneous LCMV in contrast promoting an extreme T H1 differentiation with no T FH. Single-cell RNA sequencing revealed that LCMV-specific T H1 cells comprise at least to distinct subsets, one of which expresses TCF1, which is usually expressed by T FH. We found that blocking of IFN gamma results in the transition of this atypical T-bet +TCF1 +cells into T FHcells, and in an increased number of germinal center B cells and antibodies. Our results identify IFN gamma as a molecular switch that suppresses T FHand antibody responses while supporting T H1 differentiation upon viral infection. This might be an additional mechanism whereby viruses like LCMV interfere with the generation of efficient antibody responses. Research was supported by the Italian Ministry of Education, University and Research grants SIR-RBSI14BAO5, PRIN-2017ZXT5WR and PRIN-20209Y5YFZ (to M.K.) and by the European Research Council (ERC) Consolidator Grant 725038 (to M.I.)

The LSU AgCenter Healthy Communities Initiative: Community-Participatory Policy, Systems, and Environmental Change

The LSU AgCenter Healthy Communities Initiative: Community-Participatory Policy, Systems, and Environmental Change

OA31 Real life experience of tocilizumab treatment for giant cell arteritis

Abstract Background/Aims Giant cell arteritis (GCA) has been revolutionised by fast track pathways that ensure early secure diagnosis. The GiACTA study provided evidence for the beneficial role of tocilizumab in the treatment of GCA and encouraged us all to reconsider the role of corticosteroids. These data relate to real life experience of the use of tocilizumab, including current status of patients after completing the initial year of treatment. In Scotland, tocilizumab was initially used for patients with relapsing disease or steroid complications. However, since 2018, the Scottish Medicines Consortium has supported use from disease onset and it has become increasingly common to consider adding at diagnosis. Methods The case notes of 23 patients treated with tocilizumab were reviewed back to 2017. Patient demographics were collated including whether cranial (C) or large vessel vasculitis (LVV) variant. The diagnosis of GCA had to be confirmed by biopsy or imaging with GCA rheumatology clinic review. Any patients who discontinued tocilizumab prior to completing one year had the reason recorded. Duration on tocilizumab was intended to be one year. Data were reviewed to capture outcomes after treatment was withdrawn. Results 2 patients with non-relapsing disease discontinued tocilizumab within the first month due to early relative neutropenia (1.4). 5 of 21 patients who completed treatment have since had additional tocilizumab treatment. 1 patient with particularly severe relapsing disease and steroid complications remains on long term tapered tocilizumab monotherapy without attempt to stop (C and LVV). 4 patients (LVV=C) flared within 1-9 months (median 6 months) and resumed with steroids and subsequent tapers; all had commenced for relapsing disease. 1 patient (C), commenced on tocilizumab at diagnosis, opted for MTX when flared. 15 remaining patients are on no steroid, methotrexate or tocilizumab and are free of disease activity as yet, but undergoing monitoring for flare (12C 3 LVV variant). Conclusion Tocilizumab is effective, limits steroid exposure and is well-tolerated by patients. The most common reason for discontinuing tocilizumab was relative neutropenia (neutrophils 1-1.4). The majority of patients discontinued tocilizumab and have not yet flared off all treatment. Cranial variant was less associated with relapse after tocilizumab treatment versus LVV. New diagnoses appear less prone to relapse off tocilizumab than patients already known to have relapsing disease prior to using tocilizumab. Patients discontinuing tocilizumab benefit from ongoing monitoring to recognise the early stages of returning disease; this would need to be provided for at least one year. Patients discontinuing treatment, their GPs and carers need advice on routes to escalate concerns about returning symptoms. Fast track services need to provide a flare service in addition to a diagnosis pathway if there is to be safety, confidence and expert support for this patient group and primary care colleagues. Disclosure L.M.M. Hutton: Other; 2022 Roche educational grant to attend BSR.

Can we have our cake and eat it too? Not when it comes to antiobesity medication prices

In the past 36 months, Eric A. Finkelstein has received support for serving on the WW Scientific Advisory Board and an education grant from Novo Nordisk, unrelated to the present work. Junxing Chay declared no conflict of interest.

United States‐Japan Foundation Pre‐College Education grants

Corporate Philanthropy ReportVolume 38, Issue 5 p. 13-14 Grant Alerts United States-Japan Foundation Pre-College Education grants First published: 04 April 2023 https://doi.org/10.1002/cprt.31601Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. Volume38, Issue5May 2023Pages 13-14 RelatedInformation

V11-09 PENILE VIBRATORY STIMULATION (PVS): THE METHOD OF CHOICE FOR ANEJACULATION AFTER SPINAL CORD INJURY

You have accessJournal of UrologyCME1 Apr 2023V11-09 PENILE VIBRATORY STIMULATION (PVS): THE METHOD OF CHOICE FOR ANEJACULATION AFTER SPINAL CORD INJURY Emad Ibrahim Emad IbrahimEmad Ibrahim More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003337.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Spinal cord injury (SCI) is the leading cause of anejaculation in young men. After SCI 90% of men with SCI will need a method of assisted ejaculation to achieve biological fatherhood. Penile vibratory stimulation (PVS) was popularized in 1994 after the production of the first vibrator specifically designed for semen retrieval in men with SCI. The success of this device was based on a calculated amplitude of 2.5 mm which was proven to be optimal for successfully producing an ejaculate. PVS is safe, reliable, can be performed by the male partner at home after an initial evaluation by a health care provider and yields the best sperm quality.A newly designed vibrator was produced in 2019 and was tested by a group of international experts for safety and efficacy. The study concluded the device was safe and effective in inducing ejaculation in men suffering from anejaculation after SCI. METHODS: Initial encounter: standard history, physical exam and level of injury determination using the International Standards for Neurological Classification of Spinal Cord Injury were performed. In addition, assessment of Hip Flexor Reflex and Bulbocavernosus Reflex was performed. Procedure: Patients with a level of injury at or rostral to T6 were pretreated with 10-40 mg of sublingual nifedipine to mange autonomic dysreflexia. The patient lied supine on the exam table and the vibrator was applied to the dorsum or frenulum of the glans penis. Stimulation was delivered in 2-minute increments to a maximum of 10 minutes per visit. Stimulation using 2 vibrators (Sandwich technique) or with abdominal electrical stimulation can be performed in select patients. Semen: Ejaculated semen was collected in a sterile cup and a semen analysis was performed after liquefaction. Bladder preparation using sperm wash medium was performed in patients suspected of having retrograde ejaculation. RESULTS: PVS was successful in 86% of men whose level of injury was T10 or rostral. A total of 3,698 PVS procedures were successfully performed by our group. The total motile sperm count in antegrade ejaculates produced by PVS was >5 million (lower limit considered for IUI) in 71% of ejaculates. CONCLUSIONS: PVS is a safe and effective method to manage anejaculation in men with SCI. Sperm can be obtained non surgically from most men with SCI. Sufficient sperm are available for simple insemination procedures. PVS should be considered as the method of choice for semen retrieval in this patient population. Source of Funding: Paralyzed Veterans of America (PVA) Educational Grant #877 © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1001 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Emad Ibrahim More articles by this author Expand All Advertisement PDF downloadLoading ...

"Ain't Nothing Free": Earning an Education at the Houston Junior Market Steer Auction

"Ain't Nothing Free":Earning an Education at the Houston Junior Market Steer Auction Rebecca Scofield (bio) Click for larger view View full resolution The 1943 Grand Champion steer of the Houston Fat Stock Show and Livestock Exposition (now known as Houston Livestock Show and Rodeo). Lieutenant R. B. Tate (left) and Elton Barton are shown with the champion steer at the Houston Fat Stock Show. The steer was owned by Warren Barton of Sweetwater, Texas. From Fort Worth Star-Telegram Collection, AR406-6-1705, University of Texas at Arlington Libraries, Special Collections. [End Page 494] By the mid-2010s, attendees at the junior market steer auction at the annual Houston Livestock Show and Rodeo (HLSR) were greeted by the "Hall of Champions," a long processional of the remains of past champion steers, namely their hides displayed with matted photographs of the living steer and its young owner. For decades, young people ranging from ages eight to eighteen in 4-H or FFA (once an acronym for Future Farmers of America) have exhibited between 1,800 and 2,500 steers in front of a 75,000-person audience. Competing first in local fairs throughout Texas, these exhibitors are selected as local winners and potential state-wide champions. Each year, roughly 450 of them are selected to go to the champion auction the following morning. The HLSR has not staged an ordinary stock auction, however; it has instead been a space that, according to HLSR publicity, "reward[ed] young Texas 4-H and FFA students for their hard work year round."1 Like other charity auctions, bidders have vied for social status by buying high—far higher than market-value for these animals. By 2019, a Grand Champion stock raiser was guaranteed $75,000 and, if the auction went well, allowed to receive up to $85,000. (By comparison, at an average 4-H auction sellers might have received between $1,500 and $5,000 for a Grand Champion steer).2 [End Page 495] Over the past century, students who raised champion animals for agricultural clubs have committed a great deal of time to raising their animals. It has been standard for them to spend up to five hours with the animal before dawn and after dark feeding, bathing, grooming, and exercising them.3 The young stockmen and women who appeared in Houston's arena have been overwhelmingly White, scrubbed clean, and dressed in appropriate western attire. For decades, they have represented an idealized version of the state's agricultural past and many Texans' desired future. After the daylong auction, champion sellers kissed their animals goodbye. The animals underwent drug testing, were butchered, and given back to buyers as premium beef packages. Simultaneously, organizers in Houston worked hard to wall off the chaos of the holding pens and provide a comfortable viewing area. Spectators need a metal star-shaped badge to gain entry, thus limiting seating to serious buyers ready to bid hundreds of thousands of dollars. For their anticipated generosity, the Steer Auction Committee created a buyers' breakfast and ensured audience members were provided with complimentary alcoholic beverages by a predominately African American and Latinx waitstaff. Since the 1990s, the audience has routinely consisted of real estate moguls, local CEOs, and oil barons dressed in white cowboy hats and shiny boots, eager to support the educational dreams of young people. Funds beyond the award limit of $85,000 were funneled into the Educational Fund to be distributed among seven-hundred smaller scholarships—including scholarships through 4-H and FFA, as well as ones dedicated to "Metropolitan" and "Opportunity" students, increasing the number of beneficiaries of the program and flagging the organization's educational orientation and dedication to diversity. Founded with the goal of teaching young men (and later young women) better agricultural practices, the HLSR expanded in the mid-century to provide educational resources and saw exponential growth in scholarship donations in the early twenty-first century. Ultimately, the HLSR created a huge business out of providing funds for individuals to pursue an education. As of 2019, the show had committed more than $25 million to various scholarships, educational program grants, and graduate assistantships annually. This auction exemplified a...

MP80-16 BLACK PATIENTS HAVE WORSE CONTINENCE OUTCOMES AT 12 MONTHS FOLLOWING ROBOTIC-ASSISTED RADICAL PROSTATECTOMY

You have accessJournal of UrologyCME1 Apr 2023MP80-16 BLACK PATIENTS HAVE WORSE CONTINENCE OUTCOMES AT 12 MONTHS FOLLOWING ROBOTIC-ASSISTED RADICAL PROSTATECTOMY Findlay MacAskill, Majed Shabbir, Arun Sahai, Cathcart Paul, and Noel Jonathan Findlay MacAskillFindlay MacAskill More articles by this author , Majed ShabbirMajed Shabbir More articles by this author , Arun SahaiArun Sahai More articles by this author , Cathcart PaulCathcart Paul More articles by this author , and Noel JonathanNoel Jonathan More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003357.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: It is known that racial disparities exist for oncological outcomes following prostate cancer, with black patients having a higher mortality. There remains a paucity of specific data regarding functional outcomes and ethnicity in robotic-assisted radical prostatectomy (RARP). The aim of this study was to investigate if racial disparity exists in outcomes following RARP at our institution, which covers a diverse population. METHODS: This single site study utilised an institution approved (10128) prospective database of patients that underwent primary RARP from 2020-2021 with a minimum follow up of 12 months. All 5 surgeons perform a retropubic approach. Logistic regression was performed to investigate the continence rate at 3, 6 and 12 months for significance (p<0.05). Continence is defined as 0 pads/24 hours. Further analysis was performed using propensity score matching for 12-month continence rate only. RESULTS: In this study, 232 men were included of which 37% (86) were black. On average black men underwent surgery at a younger age (59 versus 63 year). However, no difference was observed between black and white men for mean prostate volume, ISUP grade or T stage. While difference in urinary continence recovery was not significant at 3 months (36% versus 52%) and 6 months (49% versus 63%), recovery of urinary continence recovery was inferior for black men at 12 months after surgery (57% versus 75%, p=0.01). After propensity score matching, 95 white and 95 black patients were evaluated. Mean age was 61 (44-67) and 59 (43-73) years, ISUP grade 2.55 and 2.6, MRI 39 (16-112) and 28 (12-112) cc for white and black patients, respectively. Continence rate at 12 months was 76% and 60% (p=0.02), for respectively. CONCLUSIONS: The study demonstrates a racial disparity for return of urinary continence following robotic-assisted laparoscopic prostatectomy with black men having inferior recovery of urinary continence. Further work is required to investigate the reasons for the different outcome. Source of Funding: FM, MS and AS have received an unrestricted educational grant from Boston Scientific © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1159 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Findlay MacAskill More articles by this author Majed Shabbir More articles by this author Arun Sahai More articles by this author Cathcart Paul More articles by this author Noel Jonathan More articles by this author Expand All Advertisement PDF downloadLoading ...